Clinical trials: Regorafenib
Colorectal Cancer Metastatic
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
Regorafenib has demonstrated a significant benefit in overall survival in metastatic colorectal cancer (mCRC) patients. However, more than 50% of patients had severe adverse events (grade 3-4), leading to temporary or definitive…
- Trial name
- RePERSO (NCT04874207)
- Testing
- Regorafenib
- Where
- 9 sites in France
- Volunteers
- 110 people
- Sponsor
- Rennes University Hospital
Colo-rectal Cancer, PD-1 Inhibitor
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR…
- Conditions
- Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
- Trial name
- NCT06865521
- Testing
- Akkermansia Probiotics
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- West China Hospital
Carcinoma, Hepatocellular
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment.
- Trial name
- RESORCE (NCT01774344)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 147 sites in United States, Argentina and 19 more
- Volunteers
- 573 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial
- Trial name
- FOLFIRINOX-R (NCT03828799)
- Testing
- Folfirinox + regorafenib
- Where
- 4 sites in France
- Volunteers
- 13 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine.
- Trial name
- NCT07559864
- Testing
- physician-selected treatment, Regorafenib + Envafolimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Li
Rectal Cancer Stage II, Rectal Cancer Stage III
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
This is a multicenter, single-arm, phase II study of nivolumab in combination with regorafenib in subjects with locally-advanced rectal cancer who are eligible for a curative treatment including pre-operative SCRT and TME(or…
- Trial name
- REGINA (NCT04503694)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy
- Where
- 9 sites in Belgium
- Volunteers
- 72 people
- Sponsor
- Jules Bordet Institute
OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC)
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at…
- Conditions
- OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy
- Trial name
- NCT06841172
- Testing
- radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shandong Cancer Hospital and Institute
Regorafenib, Raltitrexed
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.
- Conditions
- Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment
- Trial name
- NCT05426811
- Testing
- Regorafenib, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- China Medical University, China
HCC, Transarterial Chemoembolization
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1…
- Conditions
- HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Regorafenib
- Trial name
- NCT05025592
- Testing
- Regorafenib, cTACE/DEB-TACE-HAIC
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Neoplasms
Regorafenib Post-marketing Surveillance
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for colorectal cancer.
- Trial name
- NCT01843400
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Japan
- Volunteers
- 1,301 people
- Sponsor
- Bayer
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
This study will test how well Regorafenib controls disease progression in urothelial cancer (cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous therapy with chemotherapy.
- Trial name
- NCT02459119
- Testing
- Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Ovarian Carcinoma
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
- Trial name
- REGOVAR (NCT02584465)
- Testing
- Tamoxifen, Regorafenib
- Where
- 21 sites in France
- Volunteers
- 68 people
- Sponsor
- ARCAGY/ GINECO GROUP
Colorectal Cancer
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Regorafenib in third-line treatment of metastatic colorectal cancer(mCRC) significantly prolongs the survival of patients, and its advancement has a sensitizing effect on postline chemotherapy and thus improves the prognosis of…
- Trial name
- NCT05818267
- Testing
- Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wei Zhang
Solid Tumor, Hand-Foot Skin Reaction (HFSR)
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).
- Trial name
- NCT04071756
- Testing
- Topical Tazarotene
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Colorectal Cancer
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Regorafenib is a valuable treatment option for metastatic colorectal cancer patients who have progressed after prior standard treatments.
- Trial name
- NCT01996969
- Testing
- Regorafenib
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- Seoul National University Hospital
Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival.
- Trial name
- AIO-KRK-0114 (NCT02934529)
- Testing
- Irinotecan, Folinic Acid, 5-FU
- Where
- Germany
- Volunteers
- 673 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pancreatic Cancer
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine.
- Trial name
- NCT02080260
- Testing
- regorafenib
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Colorectal Cancer
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
- Trial name
- NCT06199973
- Testing
- SHR-A1811, TAS-102, Regorafenib , Fruquintinib
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT03992456
- Testing
- Panitumumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- Academic and Community Cancer Research United
Metastatic Gastrointestinal Stromal Tumors (GIST)
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
This study is a multicenter, prospective, randomized controlled Phase II clinical trial. The primary endpoint is to evaluate the efficacy and safety of regorafenib combined with envafolimab compared to physician's choice in…
- Trial name
- NCT06772233
- Testing
- regorafenib combined with envafolimab, Control Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University